Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03333486 · OUTCOME

Lymphoid Chimerism Expressed as a Percentage of Donor Cells

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer · Source last updated 2025-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percentage of donor cells
Interval / dispersion
Standard Deviation
Time frame
At 30 days

What was measured

Mean lymphoid chimerism expressed as a percentage of donor cells

Analysis population: All treated and eligible patients. Samples were not obtained at day 100 for 8 subjects.

Groups in this outcome

Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)

Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0. Cyclophosphamide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Peripheral Blood Stem Cell Transplantation: Undergo PBSCT Total-Body Irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)23

Reported measurements

Source class 1
Values in percentage of donor cells · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)99.850.46Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.46
        value
        99.85
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Mean lymphoid chimerism expressed as a percentage of donor cells
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0. Cyclophosphamide: Given IV Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Peripheral Blood Stem Cell Transplantation: Undergo PBSCT Total-Body Irradiation: Undergo TBI
    id
    OG000
    title
    Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)
param Type
MEAN
population Description
All treated and eligible patients. Samples were not obtained at day 100 for 8 subjects.
reporting Status
POSTED
time Frame
At 30 days
title
Lymphoid Chimerism Expressed as a Percentage of Donor Cells
type
OTHER_PRE_SPECIFIED
unit Of Measure
percentage of donor cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice